BCMA-41BB-CD3 CAR-T cells

BCMA-41BB-CD3 CAR-T cells are a second-generation chimeric antigen receptor (CAR) T-cell therapy designed to target B-cell maturation antigen (BCMA), a protein highly expressed on the surface of malignant plasma cells in multiple myeloma. The CAR construct incorporates an anti-BCMA single-chain variable fragment (scFv) for antigen recognition, a 4-1BB (CD137) costimulatory domain to promote T-cell survival and persistence, and a CD3-zeta signaling domain to initiate T-cell activation and cytotoxic activity. This specific architecture is a standard design for BCMA-targeted CAR-T therapies and is being utilized in research by institutions like Hospital Israelita Albert Einstein to evaluate enhancements such as cytokine armoring (e.g., IL-15) to improve memory phenotype and therapeutic efficacy in patients with refractory or recurrent multiple myeloma.

Other names

anti-BCMA CAR-T cells